N,N- dimethyl- 5- ((2- methyl- 6- ((5- methylpyrazin- 2- yl)carbamoyl)benzofuran- 4- yl)oxy)pyrimidine- 2- carboxamide
a glucokinase activator; structure in first source
Also Known As:
PF-04937319
Networked: 2
relevant articles (1 outcomes,
2 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
| 1. | Amin, Neeta B:
1 article
(11/2016)
|
| 2. | Denham, Douglas S:
1 article
(11/2016)
|
| 3. | Denney, William S:
1 article
(11/2016)
|
| 4. | Riggs, Michael R:
1 article
(11/2016)
|
| 5. | Aggarwal, N:
1 article
(08/2015)
|
| 6. | Amin, N B:
1 article
(08/2015)
|
| 7. | Calle, R A:
1 article
(08/2015)
|
| 8. | Denney, W S:
1 article
(08/2015)
|
| 9. | Le, V:
1 article
(08/2015)
|
| 10. | Pall, D:
1 article
(08/2015)
|
Related Diseases
| 1. | Hypoglycemia (Reactive Hypoglycemia)
|
| 2. | Type 2 Diabetes Mellitus (MODY)
11/01/2016
- " In this randomized, double-blind, double-dummy, 3-period crossover phase 1b study, patients aged 18-70 years with type 2 diabetes mellitus and on metformin received once-daily PF-04937319 (300 mg), split-dose PF-04937319 (150+100 mg; breakfast+lunch), or sitagliptin (100 mg once daily). " 11/01/2016
- " Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study." 08/01/2015
- " Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes." 08/01/2015
- " To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM). "
|
|
Related Drugs and Biologics
Related Therapies and Procedures